Filing Analysis
MaxCyte, Inc. reported the results of its 2026 annual meeting of stockholders held on June 17, 2026. Stockholders approved the election of Class II Directors and ratified the selection of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual meeting held on June 17, 2026.
- Class II Directors Patrick Balthrop, Cynthia Collins, and Stanley Erck were elected.
- CohnReznick LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Proposal 2 (Auditor ratification) passed with 70,227,193 votes for and 46,732 votes against.
MaxCyte, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company received notification on June 10, 2026, that its common stock closed at or above $1.00 for 10 consecutive business days.
🚩 Red Flags
- The company's stock price has been hovering around the $1.00 threshold, indicating high volatility and proximity to delisting risks.
📋 Key Facts
- The company previously received a deficiency notice on March 16, 2026, due to the bid price falling below $1.00 for 30 consecutive trading days.
- Nasdaq confirmed compliance on June 10, 2026, based on closing prices from May 27, 2026, to June 9, 2026.
- The company is now in compliance with Nasdaq Listing Rule 5450(a)(1).
- The delisting matter is officially closed.
MaxCyte, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided an updated corporate presentation for investor communications.
📋 Key Facts
- The company issued a press release on May 12, 2026, announcing financial results for the quarter ended March 31, 2026.
- An updated corporate presentation was posted to the company's investor relations website on May 12, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The report was signed by Parmeet Ahuja, Chief Financial Officer.
MaxCyte, Inc. has appointed Parmeet Ahuja as its new Chief Financial Officer and principal accounting officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky as part of a planned leadership transition first announced in November 2025.
📋 Key Facts
- Parmeet Ahuja appointed CFO effective March 30, 2026, succeeding Douglas Swirsky.
- Mr. Ahuja previously served as Vice President of Investor Relations and Vice President of FP&A at Agilent Technologies, Inc.
- Compensation includes an annual base salary of $450,000 and a target performance bonus of 50%.
- Inducement equity grants consist of 375,000 stock options and 187,500 restricted stock units (RSUs).
- Severance terms include 12 months of salary and bonus in a change-of-control scenario, or 9 months of salary for other qualifying terminations.
MaxCyte, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided an updated corporate presentation for investors.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2025, on March 24, 2026.
- Updated corporate presentation posted to the company's investor relations website.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MaxCyte, Inc. received a deficiency notice from Nasdaq on March 16, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive trading days. The company has until September 14, 2026, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.
🚩 Red Flags
- Non-compliance with Nasdaq minimum bid price requirements.
- Potential for a reverse stock split if the share price does not recover organically.
- Risk of delisting if the company cannot meet requirements or qualify for an extension.
📋 Key Facts
- Notice received from Nasdaq on March 16, 2026, regarding non-compliance with Listing Rule 5450(a)(1).
- The stock price closed below $1.00 for 30 consecutive trading days.
- The company has an initial 180-day grace period ending September 14, 2026.
- To cure the deficiency, the stock must close at or above $1.00 for at least 10 consecutive trading days.
- If compliance is not met by the deadline, the company may apply for an additional 180-day period by transferring to the Nasdaq Capital Market.